**Early-stage preclinical and Phase 1 efforts explain the 94.5% market-implied probability against a hantavirus vaccine approval or availability in 2026.** Multiple candidates, including mRNA platforms from UTMB and collaborations involving Moderna, have shown single-dose protection and neutralizing antibody responses in animal models as recently as June 2026, yet remain far from human efficacy data or regulatory submission. No Phase 3 trials are underway, and standard development timelines from current stages exceed the remaining months of the year even under accelerated pathways. Recent outbreaks have increased visibility and prompted additional grants, but these reinforce rather than compress the required safety, immunogenicity, and manufacturing milestones. A realistic shift would require an unforeseen emergency-use authorization tied to a major public-health event combined with exceptional late-breaking data, which current surveillance and trial registries do not indicate.